Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 2196-2201, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keren, D. F.
Right arrow Articles by Lowe, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keren, D. F.
Right arrow Articles by Lowe, J. B.

Clinical Chemistry, Vol 34, 2196-2201, Copyright © 1988 by American Association for Clinical Chemistry

Strategy to diagnose monoclonal gammopathies in serum: high-resolution electrophoresis, immunofixation, and kappa/lambda quantification

DF Keren, JS Warren and JB Lowe
Department of Pathology, University of Michigan, Ann Arbor 48109.

Identification of monoclonal gammopathies in serum has involved electrophoresis of serum proteins, immunoelectrophoresis (IEP), and quantification of IgG, IgA, and IgM. Recent innovations in technology-- including high-resolution electrophoresis (HRE), immunofixation (IFX), and quantification of kappa- and lambda-containing immunoglobulins-- allow for more rapid and precise assessment of serum for monoclonal proteins. We present a series of guidelines to determine when high- resolution electrophoresis and quantification of immunoglobulins (including kappa and lambda) are sufficient and when additional IFX is required to characterize the monoclonal gammopathy. Of the samples studied, 88% were correctly diagnosed by HRE with quantification of immunoglobulins and kappa/lambda; only 12% required that IFX be performed. The guidelines allow us to detect monoclonal gammopathies quicker and more efficiently by avoiding redundant IEP or IFX testing. For the vast majority of cases, these guidelines allow for a correct diagnosis within one day. After one year of follow-up since completion of the study, no undetected cases of monoclonal gammopathy have eventuated.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C. Gay-Bellile, D. Bengoufa, P. Houze, D. Le Carrer, M. Benlakehal, B. Bousquet, B. Gourmel, and T. Le Bricon
Automated Multicapillary Electrophoresis for Analysis of Human Serum Proteins
Clin. Chem., November 1, 2003; 49(11): 1909 - 1915.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
K. C. Gorson, A. H. Ropper, D. H. Weinberg, and R. Weinstein
Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy
Arch Neurol, May 1, 2002; 59(5): 766 - 772.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Attaelmannan and S. S. Levinson
Understanding and Identifying Monoclonal Gammopathies
Clin. Chem., August 1, 2000; 46(8): 1230 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K. C Gorson and A. H Ropper
Axonal neuropathy associated with monoclonal gammopathy of undetermined significance
J. Neurol. Neurosurg. Psychiatry, August 1, 1997; 63(2): 163 - 168.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.